• Explore /
  • Poster
  • / The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).

The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).

Abstract Poster

Authors

Arndt Vogel

Arndt Vogel

Hannover Medical School, Hannover, Germany

Arndt Vogel , Thorsten Oliver Goetze , Guido Hausner , Michael Geißler , Gabriele Margareta Siegler , Ludwig Fischer von Weikersthal , Angelika M. R. Kestler , Matthias Kleiß , Tobias Müller , Andreas Teufel , Jens Marquardt , Maria A Gonzalez-Carmona , Daniel Wilhelm Mueller , Regina Eickhoff , Enrico N. de Toni , Oliver Waidmann , Salah-Eddin Al-Batran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03753659

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4159)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4159

Abstract #

TPS4159

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Glenn J. Hanna

First Author: Montaser F. Shaheen

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

First Author: David Hsieh